Health
Galderma Announces First Patient Enrollment in Study to Assess Nemolizumab in Adults With Chronic Pruritus of Unknown Origin
ZUG, Switzerland, December 11, 2025--Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the first patient enrollment for its phase II study investigating the efficacy and safety of nemolizumab in treating patients living with Chronic Pruritus of Unknown Origin (CPUO). The first patient of the trial – which is taking place in the United States – was enrolled at Dr. Vlada Groysman’s site in Birmingham, Alabama.
About this update from Galderma Group Ag
[{"type":"image","alt":"Dr. Christophe Piketty, Global Program Head Therapeutic Dermatology, Galderma; Dr. Shawn Kwatra, Lead Investigator, Chronic Pruritus of Unknown Origin Phase II Study","displaySize":"","headline":null,"caption":"Dr. Christophe Piketty, Global Program Head Therapeutic Dermatology, Galderma; Dr. Shawn Kwatra, Lead Investigator, Chronic Pruritus of Unknown Origin Phase II Study","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1920,"height":1080,"url":"https://media.zenfs.com/en/business-wire.com/0db79e7c56801a21442c9e15ce419160"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/0Atvo2su_hlmJTgmCCKWTQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU0MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/0db79e7c56801a21442c9e15ce419160","width":960,"height":540},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/domMMtMw8MnviK.5XbEX0Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0xMzUwO2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/0db79e7c56801a21442c9e15ce419160","width":1200,"height":675}},"lazy":false},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":823,"height":209,"url":"https://media.zenfs.com/en/business-wire.com/b0345f4408f2e9a0ea1841426ea2f451"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/vrXZ5HOt17OeULCZHj6CUw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTI0NDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/b0345f4408f2e9a0ea1841426ea2f451","width":823,"height":209},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/YhuP8hWX0ScNDs850yEnEg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTE2NDY7aD00MTg7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/b0345f4408f2e9a0ea1841426ea2f451","width":823,"height":209}}},{"type":"list","items":[{"val":[{"type":"text","content":"Chronic Pruritus of Unknown Origin (CPUO) is characterized by a persistent, chronic itch with an unknown cause and is associated with very high burden of disease due to severe itch, sleep deprivation and mental distress1","length":220,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Galderma’s phase II study builds on emerging research that reinforces the role of IL-31 – a neuroimmune cytokine that is involved in driving itch – in CPUO1","length":156,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"...